UNSPSC 51162351: Chlorpheniramine/methscopolamine/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

UNSPSC 51162351 Chlorpheniramine/methscopolamine/pseudoephedrine is a Commodity code that in recent state and local practice captures pharmaceutical procurement spanning naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products distributed through public health and safety networks. State and local issuing bodies range from county health departments and special-purpose districts managing opioid response initiatives to multistate cooperative purchasing alliances coordinating pharmaceutical supply across state and local government facilities. The work involves competitive procurement of finished pharmaceutical products with specified National Drug Codes, dosage forms, packaging configurations, and manufacturing compliance certifications—including current Good Manufacturing Practices and Drug Supply Chain Security Act attestations—delivered either directly to local health facilities or through authorized wholesale distributors to member jurisdictions.

Recent activity appears concentrated in the Southeast and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response deadline July 26, 2023. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon, with proposals due March 26, 2026; the RFP weighted price competitiveness at 75 percent, required cGMP and DSCSA compliance, and mandated contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). Both solicitations required E-Verify compliance, workers' compensation and commercial general liability insurance, and fixed-fee or tiered pricing structures.